AcuCort AB has recently published the results of its Phase IV study, ZEQ001, in the Journal of Market Access & Health Policy, highlighting the effectiveness and patient preference for their innovative product, Zeqmelit® oral film. The study, which included 50 patients, was conducted in a real-world clinical setting and focused on evaluating patient experiences with Zeqmelit® compared to traditional betamethasone tablets.

Key findings from the study are promising, with 98% of participants expressing satisfaction with the availability of Zeqmelit® compared to only 58% for the tablets. The convenience of the oral film formulation led to 77% of patients carrying Zeqmelit® more frequently, and 78% feeling more secure having it on hand. In acute allergic reactions, Zeqmelit® was chosen in 16 out of 18 cases, with a 94% effectiveness rating as good or very good.

These results not only underscore the product's efficacy but also its potential to enhance patient compliance and treatment accessibility. CEO Jonas Jönmark emphasized the importance of these findings as AcuCort embarks on international expansion, leveraging the study's publication as a testament to the product's scientific and market value.

Given the positive patient feedback and the strategic timing of the study's publication, AcuCort is poised for growth in new markets. The oral film's user-friendly format, coupled with its effectiveness, positions Zeqmelit® as a competitive alternative to traditional corticosteroid tablets.

For investors, the study's outcomes suggest a promising trajectory for AcuCort's market performance. The demonstrated preference for Zeqmelit® over tablets could drive increased demand and support the company's expansion efforts. However, potential investors should consider the broader market dynamics and regulatory landscapes in the targeted international markets.

In conclusion, AcuCort's innovative approach with Zeqmelit® presents a compelling case for investment. The company's strategic focus on patient-centric solutions and its readiness for international growth make it a strong candidate for a "buy" recommendation, contingent on continued positive market reception and regulatory support.